Acute evere viual acuity decreae after photodynamic therapy with verteporfin: cae report from randomized clinical trial—TAP and VIP report no. 3

Purpoe To decribe in detail occurrence of acute evere viual acuity decreae after photodynamic therapy (PDT) with verteporfin in the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Invetigation and the Verteporfin In Photodynamic therapy (VIP) Trial. Deign Obervational cae erie. Method Retropective review of all cae that developed acute evere viual acuity decreae after treatment. Reult Of 15 acute evere viual acuity decreae event originally identified in 14 eye of 14 patient, one event in one patient wa judged unlikely to have been an acute evere viual acuity decreae event on retropective review of thee event in preparation of thi report. Eleven event occurred after the firt treatment. At follow-up, 10 improved by at leat 1 line in viual acuity from the level noted at the time of the event. Of the nine patient returning for the month 24 examination, viual acuity decreaed at leat 3 line from baeline in ix, including at leat 6 line in four, and remained within 1 line in three. Aociated abnormal morphology included three with a erou macular detachment and abnormal choroidal hypofluorecence, four with macular hemorrhage, three with a greenih ubfoveal hemorrhage, and four with no abnormality. Event appeared to be more likely when patient had a viual acuity of 20/50 or better. Concluion Acute evere viual acuity decreae after PDT with verteporfin wa an uncommon event; the rik did not outweigh the benefit of therapy previouly reported. When conidering verteporfin therapy, patient hould be warned of the poibility of thi eriou advere event.